Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study.

Ward, Helen; Atchison, Christina; Whitaker, Matthew; Davies, Bethan; Ashby, Deborah; Darzi, Ara; Chadeau-Hyam, Marc; Riley, Steven et al. · Am J Public Health · 2023

cross_sectional · Level IV

Where this comes from

Abstract

<b>Data System.</b> The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England. <b>Data Collection/Processing.</b> We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020-May 2021). <b>Data Analysis/Dissemination.</b> We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications. <b>Public Health Implications.</b> REACT-2 estimated the scale and variation in antibody prevalence over time. Community self-testing and -reporting produced rapid insights into the changing course of the pandemic and the impact of vaccine rollout, with implications for future surveillance. (<i>Am J Public Health.</i> 2023;113(11):1201-1209. https://doi.org/10.2105/AJPH.2023.307381).

Medical subject headings